drugset / Trial / NCT07020923
Monthly Dosing of Atacicept in IgAN
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
Timeline
- Start
- 2025-05-29
- Primary completion
- 2026-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atacicept | Protein / enzyme biologic | — | Subcutaneous |